MedTrace Logo

A Phase I Study of HRS2300 or Combined With SHR-1316 or SHR-1701 or Trametinib or Almonertinib in Patients With Advanced Malignancies

NCT05048134 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2024-09-19

No results posted yet for this study

Summary

The study is being conducted to evaluate the safety and tolerability of HRS2300 and combined with SHR-1316 or SHR-1701 or trametinib or Almonertinib.To Determine the maximum tolerated dose (MTD) and recommended Dose (RP2D) for HRS2300 monotherapy and combination therapy.

Conditions

  • Advanced Malignancies

Interventions

DRUG

HRS2300

HRS2300 monotherapy

DRUG

HRS2300、 SHR-1316

HRS2300 combined with SHR-1316

DRUG

HRS2300、SHR-1701

HRS2300 combined with SHR-1701

DRUG

HRS2300、trametinib

HRS2300 combined with trametinib

DRUG

HRS2300、Almonertinib

HRS2300 combined with Almonertinib

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-25
Primary Completion
2023-02-24
Completion
2023-05-23

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05048134 on ClinicalTrials.gov